GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. Their research and development focus on four therapeutic areas: infectious diseases, HIV, oncology, and immunology and applying their capabilities in human genetics, advanced technologies, vaccines and medicines development.

About the Oxford-GSK Alliance

GSK and the University of Oxford work collaboratively on research projects in functional genomics, digital biomarkers, neurodegeneration, immunology, and pain.  These projects aim to transform the understanding of how genetics influence disease and enable the identification of novel and high-quality validated targets and derive novel digital biomarkers to develop clinically meaningful outcome measures.

Building on this strong relationship, the multi-disciplinary Oxford-GSK Institute of Molecular and Computational Medicine (IMCM) was launched in 2022, pioneering a new model of academic-industry collaboration. Initially focussing on neurodegenerative diseases, the aim of the Institute is to improve tools in, and knowledge from, genetics, genomics, molecular and single cell biology, spatial imaging, machine learning and novel methods of data handling to study the pattern of diseases in new ways.